Zynaxis Inc Sample Contracts

AutoNDA by SimpleDocs
GUARANTY
Guaranty • March 27th, 1997 • Zynaxis Inc • Pharmaceutical preparations • Georgia
WITNESSETH
Agreement of Lease • March 27th, 1997 • Zynaxis Inc • Pharmaceutical preparations
Background ----------
Secured Loan Agreement • March 27th, 1997 • Zynaxis Inc • Pharmaceutical preparations • Georgia
ARTICLE II REPRESENTATIONS AND WARRANTIES OF ZYNAXIS
Technology Development Agreement • March 27th, 1997 • Zynaxis Inc • Pharmaceutical preparations • Georgia
SUBLANDLORD: SUBTENANT:
Sublease Cancellation Agreement • March 27th, 1997 • Zynaxis Inc • Pharmaceutical preparations

WHEREAS, on the 23rd day of August, 1988, a certain Lease (the "Lease") was entered into by and between Rouse & Associates - 335 Phoenixville Pike Limited Partnership ("Landlord") and Zynaxis Cell Science Inc. ("Tenant") for a portion of a building located at 371 Phoenixville Pike, Malvern, PA 19355 (the "Premises") and, thereafter, PMRA III, a California Group Trust, c/o PMRA Realty Advisors, a California corporation, 800 Newport Center Drive, Suite 300, Newport Beach, CA 92660 succeeded to the title and interest in the Premises by Deed from Rouse & Associates on May 2, 1989. The Lease was amended December 1, 1992.

PHANOS TECHNOLOGIES, INC. C/O CYBERSTUDIOS 8559 HIGUERA ST. CULVER CITY, CA 90232 October 17, 1996 Martyn Greenacre Zynaxis, Inc. 371 Phoenixville Pike Malvern, PA 19355 RE: EXCLUSIVE LICENSE AGREEMENT WITH PURCHASE OPTION Dear Martyn: Reference is...
License Agreement • November 12th, 1996 • Zynaxis Inc • Pharmaceutical preparations

PHANOS TECHNOLOGIES, INC. C/O CYBERSTUDIOS 8559 HIGUERA ST. CULVER CITY, CA 90232 October 17, 1996 Martyn Greenacre Zynaxis, Inc. 371 Phoenixville Pike Malvern, PA 19355 RE: EXCLUSIVE LICENSE AGREEMENT WITH PURCHASE OPTION Dear Martyn: Reference is made to the signed Exclusive License Agreement with Purchase Option dated September 23, 1996 (the "Agreement") between Phanos Technologies, Inc. and Zynaxis, Inc. Paragraph 4 of the Agreement is hereby amended to provide that the $150,000 portion of the Exclusive License Fee described therein be payable $75,000 on October 18, 1996 and $75,000 on October 23, 1996. Paragraph 5 is amended to provide that the Running Royalties on Sales will terminate upon the expiration of the last patent included in the Zynaxis Information. Paragraph 11 is amended to provide that Phanos may disclose the Zynaxis Information to a third party if that third party has entered into a Confidentiality Agreement with Phanos in a form reasonably acceptable to Zynaxis. Th

Time is Money Join Law Insider Premium to draft better contracts faster.